schliessen

Filtern

 

Bibliotheken

In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects

Purpose To assess the in vitro activity of cefiderocol (CFDC) against a collection of both ceftazidime-avibactam (CZA) susceptible and resistant KPC-producing Enterobacterales (KPC-EB) isolates. Secondly, to assess its synergistic activity in combination with different antibiotics. Methods One hundr... Full description

Journal Title: European journal of clinical microbiology & infectious diseases 2021-08-31, Vol.41 (1), p.63-70
Main Author: Bianco, Gabriele
Other Authors: Boattini, Matteo , Comini, Sara , Iannaccone, Marco , Bondi, Alessandro , Cavallo, Rossana , Costa, Cristina
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Berlin/Heidelberg: Springer Berlin Heidelberg
ID: ISSN: 0934-9723
Link: https://www.ncbi.nlm.nih.gov/pubmed/34462816
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_2567988608
title: In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects
format: Article
creator:
  • Bianco, Gabriele
  • Boattini, Matteo
  • Comini, Sara
  • Iannaccone, Marco
  • Bondi, Alessandro
  • Cavallo, Rossana
  • Costa, Cristina
subjects:
  • Amikacin
  • Anti-Bacterial Agents - pharmacology
  • Antibiotics
  • Azabicyclo Compounds - pharmacology
  • Bacterial pneumonia
  • Bacterial Proteins - genetics
  • Bacterial Proteins - metabolism
  • beta-Lactamases - genetics
  • beta-Lactamases - metabolism
  • Biomedical and Life Sciences
  • Biomedicine
  • Breakpoints
  • Ceftazidime
  • Ceftazidime - pharmacology
  • Cephalosporins - pharmacology
  • Cross-resistance
  • Diffusion
  • Diffusion rate
  • Drug Combinations
  • Drug resistance in microorganisms
  • Drug Resistance, Bacterial
  • Drug Synergism
  • Enterobacterales
  • Enzymes
  • Evaluation
  • Humans
  • Imipenem
  • Infectious diseases
  • Internal Medicine
  • Klebsiella
  • Klebsiella Infections - drug therapy
  • Klebsiella Infections - microbiology
  • Klebsiella pneumoniae - drug effects
  • Klebsiella pneumoniae - genetics
  • Klebsiella pneumoniae - metabolism
  • Laboratories
  • Medical Microbiology
  • Meropenem
  • Microbial Sensitivity Tests
  • Original Article
  • Pneumonia
  • Quality control
  • Surveillance
  • Synergistic effect
  • β Lactamase
ispartof: European journal of clinical microbiology & infectious diseases, 2021-08-31, Vol.41 (1), p.63-70
description: Purpose To assess the in vitro activity of cefiderocol (CFDC) against a collection of both ceftazidime-avibactam (CZA) susceptible and resistant KPC-producing Enterobacterales (KPC-EB) isolates. Secondly, to assess its synergistic activity in combination with different antibiotics. Methods One hundred KPC-EB isolates were tested: 60 CZA susceptible and 40 CZA resistant. Among them, 17 pairs of CZA susceptible and resistant KPC-producing Klebsiella pneumoniae (KPC-Kp) isolates were collected from 17 distinct patients before and after CZA treatment, respectively. CFDC susceptibility was evaluated by both broth microdilution (lyophilized panels; Sensititre; Thermo Fisher) and disk diffusion testing. Results were interpreted using EUCAST breakpoints. Synergistic activity of CFDC in combination with CZA, meropenem-vaborbactam, imipenem, and amikacin against six characterized KPC-Kp strains, before and after acquisition of CZA resistance, was evaluated using gradient diffusion strip crossing method. Results CFDC resistance rate was significantly higher in CZA resistant EB subset than in the susceptible one ( p  
language: eng
source:
identifier: ISSN: 0934-9723
fulltext: no_fulltext
issn:
  • 0934-9723
  • 1435-4373
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6141443
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_2567988608
sourceformatXML
sourcesystemPC
galeidA688797468
sourcerecordidA688797468
originalsourceidFETCH-LOGICAL-c357t-64dc208589932b4abe839fb009f393ed4cfbd4e115744069dd3ed6eaa48b53be0
addsrcrecordideNp9Uc2KFDEYbERxx9UX8CABL16ypjvp_HhbhlUXF_Sg55BOvgxZutNjkl6YeRvf1Mz2roIHCSShUlVUvmqa1y25aAkR73PdFcekazFhlLX4-KTZtIz2mFFBnzYboijDSnT0rHmR8y2pIinE8-aMMsY72fJN8-s6ortQ0oyMLaHeDmj2yIIPDtJs5xGZnQkxlxNWzDG4MAE2d2GofDOhvGQL-xKGEZCJDiXIIRcTC_rybYv3aXaLDXGHrmKpficRJDNC_oBsmnPGj3y7yvMhQtpVJFgE3oMt-WXzzJsxw6uH87z58fHq-_Yzvvn66Xp7eYMt7UXBnDnbEdlLpWg3MDOApMoPdUKeKgqOWT84Bm3bC8YIV85VkIMxTA49HYCcN-9W3xr65wK56CnUv42jiTAvWXc9F0pKTmSlvv2HejsvKdZ0uuMtF5L2RFXWxcra1Q_rEP1ckrF1OZiCnWOdccUvuZRCCcZPtt0quB9NAq_3KUwmHXRL9KlxvTaua-P6vnF9rKI3D1mWYQL3R_JYcSXQlZDrU9xB-hv2P7a_AZQBuvs
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid2616783509
display
typearticle
titleIn vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects
creatorBianco, Gabriele ; Boattini, Matteo ; Comini, Sara ; Iannaccone, Marco ; Bondi, Alessandro ; Cavallo, Rossana ; Costa, Cristina
creatorcontribBianco, Gabriele ; Boattini, Matteo ; Comini, Sara ; Iannaccone, Marco ; Bondi, Alessandro ; Cavallo, Rossana ; Costa, Cristina
descriptionPurpose To assess the in vitro activity of cefiderocol (CFDC) against a collection of both ceftazidime-avibactam (CZA) susceptible and resistant KPC-producing Enterobacterales (KPC-EB) isolates. Secondly, to assess its synergistic activity in combination with different antibiotics. Methods One hundred KPC-EB isolates were tested: 60 CZA susceptible and 40 CZA resistant. Among them, 17 pairs of CZA susceptible and resistant KPC-producing Klebsiella pneumoniae (KPC-Kp) isolates were collected from 17 distinct patients before and after CZA treatment, respectively. CFDC susceptibility was evaluated by both broth microdilution (lyophilized panels; Sensititre; Thermo Fisher) and disk diffusion testing. Results were interpreted using EUCAST breakpoints. Synergistic activity of CFDC in combination with CZA, meropenem-vaborbactam, imipenem, and amikacin against six characterized KPC-Kp strains, before and after acquisition of CZA resistance, was evaluated using gradient diffusion strip crossing method. Results CFDC resistance rate was significantly higher in CZA resistant EB subset than in the susceptible one ( p  < 0.001): 82.5% vs 6.7%. MIC50 and MIC90 values were 0.25 and 2 mg/L, 8 and 64 mg/L in CZA-susceptible and CZA-resistant subset, respectively. KPC-Kp isolates harboring KPC-D179Y or KPC-Δ242-GT-243 variants showed CFDC MICs ranging from 4 to 64 mg/L. CFDC showed in vitro synergistic effect mostly with CZA, against both CZA susceptible and resistant isolates, resulting in a synergy rate of 66.7%. Conclusions CZA resistance mechanisms in KPC-EB impair the in vitro activity of CFDC, often leading to co-resistance. CFDC in combination with the new β-lactamases inhibitors might represent a strategy to enhance its activity.
identifier
0ISSN: 0934-9723
1EISSN: 1435-4373
2DOI: 10.1007/s10096-021-04341-z
3PMID: 34462816
languageeng
publisherBerlin/Heidelberg: Springer Berlin Heidelberg
subjectAmikacin ; Anti-Bacterial Agents - pharmacology ; Antibiotics ; Azabicyclo Compounds - pharmacology ; Bacterial pneumonia ; Bacterial Proteins - genetics ; Bacterial Proteins - metabolism ; beta-Lactamases - genetics ; beta-Lactamases - metabolism ; Biomedical and Life Sciences ; Biomedicine ; Breakpoints ; Ceftazidime ; Ceftazidime - pharmacology ; Cephalosporins - pharmacology ; Cross-resistance ; Diffusion ; Diffusion rate ; Drug Combinations ; Drug resistance in microorganisms ; Drug Resistance, Bacterial ; Drug Synergism ; Enterobacterales ; Enzymes ; Evaluation ; Humans ; Imipenem ; Infectious diseases ; Internal Medicine ; Klebsiella ; Klebsiella Infections - drug therapy ; Klebsiella Infections - microbiology ; Klebsiella pneumoniae - drug effects ; Klebsiella pneumoniae - genetics ; Klebsiella pneumoniae - metabolism ; Laboratories ; Medical Microbiology ; Meropenem ; Microbial Sensitivity Tests ; Original Article ; Pneumonia ; Quality control ; Surveillance ; Synergistic effect ; β Lactamase
ispartofEuropean journal of clinical microbiology & infectious diseases, 2021-08-31, Vol.41 (1), p.63-70
rights
0The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021
12021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
2COPYRIGHT 2022 Springer
3The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.
lds50peer_reviewed
citesFETCH-LOGICAL-c357t-64dc208589932b4abe839fb009f393ed4cfbd4e115744069dd3ed6eaa48b53be0
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34462816$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Bianco, Gabriele
1Boattini, Matteo
2Comini, Sara
3Iannaccone, Marco
4Bondi, Alessandro
5Cavallo, Rossana
6Costa, Cristina
title
0In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects
1European journal of clinical microbiology & infectious diseases
addtitle
0Eur J Clin Microbiol Infect Dis
1Eur J Clin Microbiol Infect Dis
descriptionPurpose To assess the in vitro activity of cefiderocol (CFDC) against a collection of both ceftazidime-avibactam (CZA) susceptible and resistant KPC-producing Enterobacterales (KPC-EB) isolates. Secondly, to assess its synergistic activity in combination with different antibiotics. Methods One hundred KPC-EB isolates were tested: 60 CZA susceptible and 40 CZA resistant. Among them, 17 pairs of CZA susceptible and resistant KPC-producing Klebsiella pneumoniae (KPC-Kp) isolates were collected from 17 distinct patients before and after CZA treatment, respectively. CFDC susceptibility was evaluated by both broth microdilution (lyophilized panels; Sensititre; Thermo Fisher) and disk diffusion testing. Results were interpreted using EUCAST breakpoints. Synergistic activity of CFDC in combination with CZA, meropenem-vaborbactam, imipenem, and amikacin against six characterized KPC-Kp strains, before and after acquisition of CZA resistance, was evaluated using gradient diffusion strip crossing method. Results CFDC resistance rate was significantly higher in CZA resistant EB subset than in the susceptible one ( p  < 0.001): 82.5% vs 6.7%. MIC50 and MIC90 values were 0.25 and 2 mg/L, 8 and 64 mg/L in CZA-susceptible and CZA-resistant subset, respectively. KPC-Kp isolates harboring KPC-D179Y or KPC-Δ242-GT-243 variants showed CFDC MICs ranging from 4 to 64 mg/L. CFDC showed in vitro synergistic effect mostly with CZA, against both CZA susceptible and resistant isolates, resulting in a synergy rate of 66.7%. Conclusions CZA resistance mechanisms in KPC-EB impair the in vitro activity of CFDC, often leading to co-resistance. CFDC in combination with the new β-lactamases inhibitors might represent a strategy to enhance its activity.
subject
0Amikacin
1Anti-Bacterial Agents - pharmacology
2Antibiotics
3Azabicyclo Compounds - pharmacology
4Bacterial pneumonia
5Bacterial Proteins - genetics
6Bacterial Proteins - metabolism
7beta-Lactamases - genetics
8beta-Lactamases - metabolism
9Biomedical and Life Sciences
10Biomedicine
11Breakpoints
12Ceftazidime
13Ceftazidime - pharmacology
14Cephalosporins - pharmacology
15Cross-resistance
16Diffusion
17Diffusion rate
18Drug Combinations
19Drug resistance in microorganisms
20Drug Resistance, Bacterial
21Drug Synergism
22Enterobacterales
23Enzymes
24Evaluation
25Humans
26Imipenem
27Infectious diseases
28Internal Medicine
29Klebsiella
30Klebsiella Infections - drug therapy
31Klebsiella Infections - microbiology
32Klebsiella pneumoniae - drug effects
33Klebsiella pneumoniae - genetics
34Klebsiella pneumoniae - metabolism
35Laboratories
36Medical Microbiology
37Meropenem
38Microbial Sensitivity Tests
39Original Article
40Pneumonia
41Quality control
42Surveillance
43Synergistic effect
44β Lactamase
issn
00934-9723
11435-4373
fulltextfalse
rsrctypearticle
creationdate2021
recordtypearticle
recordideNp9Uc2KFDEYbERxx9UX8CABL16ypjvp_HhbhlUXF_Sg55BOvgxZutNjkl6YeRvf1Mz2roIHCSShUlVUvmqa1y25aAkR73PdFcekazFhlLX4-KTZtIz2mFFBnzYboijDSnT0rHmR8y2pIinE8-aMMsY72fJN8-s6ortQ0oyMLaHeDmj2yIIPDtJs5xGZnQkxlxNWzDG4MAE2d2GofDOhvGQL-xKGEZCJDiXIIRcTC_rybYv3aXaLDXGHrmKpficRJDNC_oBsmnPGj3y7yvMhQtpVJFgE3oMt-WXzzJsxw6uH87z58fHq-_Yzvvn66Xp7eYMt7UXBnDnbEdlLpWg3MDOApMoPdUKeKgqOWT84Bm3bC8YIV85VkIMxTA49HYCcN-9W3xr65wK56CnUv42jiTAvWXc9F0pKTmSlvv2HejsvKdZ0uuMtF5L2RFXWxcra1Q_rEP1ckrF1OZiCnWOdccUvuZRCCcZPtt0quB9NAq_3KUwmHXRL9KlxvTaua-P6vnF9rKI3D1mWYQL3R_JYcSXQlZDrU9xB-hv2P7a_AZQBuvs
startdate20210831
enddate20210831
creator
0Bianco, Gabriele
1Boattini, Matteo
2Comini, Sara
3Iannaccone, Marco
4Bondi, Alessandro
5Cavallo, Rossana
6Costa, Cristina
general
0Springer Berlin Heidelberg
1Springer
2Springer Nature B.V
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
97QL
107U9
11C1K
12H94
13K9.
14M7N
157X8
sort
creationdate20210831
titleIn vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects
authorBianco, Gabriele ; Boattini, Matteo ; Comini, Sara ; Iannaccone, Marco ; Bondi, Alessandro ; Cavallo, Rossana ; Costa, Cristina
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c357t-64dc208589932b4abe839fb009f393ed4cfbd4e115744069dd3ed6eaa48b53be0
rsrctypearticles
prefilterarticles
languageeng
creationdate2021
topic
0Amikacin
1Anti-Bacterial Agents - pharmacology
2Antibiotics
3Azabicyclo Compounds - pharmacology
4Bacterial pneumonia
5Bacterial Proteins - genetics
6Bacterial Proteins - metabolism
7beta-Lactamases - genetics
8beta-Lactamases - metabolism
9Biomedical and Life Sciences
10Biomedicine
11Breakpoints
12Ceftazidime
13Ceftazidime - pharmacology
14Cephalosporins - pharmacology
15Cross-resistance
16Diffusion
17Diffusion rate
18Drug Combinations
19Drug resistance in microorganisms
20Drug Resistance, Bacterial
21Drug Synergism
22Enterobacterales
23Enzymes
24Evaluation
25Humans
26Imipenem
27Infectious diseases
28Internal Medicine
29Klebsiella
30Klebsiella Infections - drug therapy
31Klebsiella Infections - microbiology
32Klebsiella pneumoniae - drug effects
33Klebsiella pneumoniae - genetics
34Klebsiella pneumoniae - metabolism
35Laboratories
36Medical Microbiology
37Meropenem
38Microbial Sensitivity Tests
39Original Article
40Pneumonia
41Quality control
42Surveillance
43Synergistic effect
44β Lactamase
toplevelpeer_reviewed
creatorcontrib
0Bianco, Gabriele
1Boattini, Matteo
2Comini, Sara
3Iannaccone, Marco
4Bondi, Alessandro
5Cavallo, Rossana
6Costa, Cristina
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8Bacteriology Abstracts (Microbiology B)
9Virology and AIDS Abstracts
10Environmental Sciences and Pollution Management
11AIDS and Cancer Research Abstracts
12ProQuest Health & Medical Complete (Alumni)
13Algology Mycology and Protozoology Abstracts (Microbiology C)
14MEDLINE - Academic
jtitleEuropean journal of clinical microbiology & infectious diseases
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Bianco, Gabriele
1Boattini, Matteo
2Comini, Sara
3Iannaccone, Marco
4Bondi, Alessandro
5Cavallo, Rossana
6Costa, Cristina
formatjournal
genrearticle
ristypeJOUR
atitleIn vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects
jtitleEuropean journal of clinical microbiology & infectious diseases
stitleEur J Clin Microbiol Infect Dis
addtitleEur J Clin Microbiol Infect Dis
date2021-08-31
risdate2021
volume41
issue1
spage63
epage70
pages63-70
issn0934-9723
eissn1435-4373
abstractPurpose To assess the in vitro activity of cefiderocol (CFDC) against a collection of both ceftazidime-avibactam (CZA) susceptible and resistant KPC-producing Enterobacterales (KPC-EB) isolates. Secondly, to assess its synergistic activity in combination with different antibiotics. Methods One hundred KPC-EB isolates were tested: 60 CZA susceptible and 40 CZA resistant. Among them, 17 pairs of CZA susceptible and resistant KPC-producing Klebsiella pneumoniae (KPC-Kp) isolates were collected from 17 distinct patients before and after CZA treatment, respectively. CFDC susceptibility was evaluated by both broth microdilution (lyophilized panels; Sensititre; Thermo Fisher) and disk diffusion testing. Results were interpreted using EUCAST breakpoints. Synergistic activity of CFDC in combination with CZA, meropenem-vaborbactam, imipenem, and amikacin against six characterized KPC-Kp strains, before and after acquisition of CZA resistance, was evaluated using gradient diffusion strip crossing method. Results CFDC resistance rate was significantly higher in CZA resistant EB subset than in the susceptible one ( p  < 0.001): 82.5% vs 6.7%. MIC50 and MIC90 values were 0.25 and 2 mg/L, 8 and 64 mg/L in CZA-susceptible and CZA-resistant subset, respectively. KPC-Kp isolates harboring KPC-D179Y or KPC-Δ242-GT-243 variants showed CFDC MICs ranging from 4 to 64 mg/L. CFDC showed in vitro synergistic effect mostly with CZA, against both CZA susceptible and resistant isolates, resulting in a synergy rate of 66.7%. Conclusions CZA resistance mechanisms in KPC-EB impair the in vitro activity of CFDC, often leading to co-resistance. CFDC in combination with the new β-lactamases inhibitors might represent a strategy to enhance its activity.
copBerlin/Heidelberg
pubSpringer Berlin Heidelberg
pmid34462816
doi10.1007/s10096-021-04341-z